Scarica l'app Stockscreener
32.31
2.83%
-0.94
Dopo l'orario di chiusura:
32.31
Collegium Pharmaceutical Inc Borsa (COLL) Ultime notizie
Chipmakers Recap: Should I hold or sell Collegium Pharmaceutical Inc now2026 Highlights & Reliable Volume Spike Alerts - baoquankhu1.vn
COLL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Pullback - Sahm
Is Collegium Pharmaceutical (COLL) one of the best small-cap drug manufacturers? - msn.com
Collegium (COLL) EVP has 8,840 shares withheld for RSU tax payment - Stock Titan
Collegium Pharmaceutical (COLL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To Know - Yahoo Finance
COLL Stock Price, Quote & Chart | COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) - ChartMill
Collegium Pharmaceutical (COLL) surged following record quarterly results - msn.com
Collegium Pharmaceutical, Inc. (COLL) Stock Forecasts - Yahoo Finance
Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million - AOL.com
Collegium Pharma Executive David Dieter Sells Shares in March 2026News and Statistics - IndexBox
Collegium Pharmaceutical Acquires AZSTARYS for $650M - National Today
Is Collegium Pharmaceutical (COLL) One of the Best Small-Cap Drug Manufacturers - Insider Monkey
Aug Volume: Can Collegium Pharmaceutical Inc be the next market leaderSell Signal & AI Enhanced Trading Alerts - baoquankhu1.vn
JPMorgan Chase & Co. Acquires 139,689 Shares of Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD - The Motley Fool
Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD - The Motley Fool
Wedge Capital Management L L P NC Acquires New Stake in Collegium Pharmaceutical, Inc. $COLL - marketbeat.com
Published on: 2026-03-30 05:44:15 - baoquankhu1.vn
Collegium Pharmaceutical Inc (NASDAQ:COLL) Presents a Compelling Value Investment Case - ChartMill
COLL SEC FilingsCollegium Pharmaceutical Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is It Time To Reassess Collegium Pharmaceutical (COLL) After The Recent Share Price Pullback? - simplywall.st
Collegium’s AZSTARYS Deal And Insider Sale Put Focus On Valuation - Yahoo Finance
Vanguard disaggregates holdings; reports 0 shares in Collegium (COLL) - Stock Titan
Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL) - Yahoo Finance
Collegium Pharmaceutical, Inc. $COLL Shares Bought by Assenagon Asset Management S.A. - marketbeat.com
Collegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025 - MSN
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Medline (MDLN) and Collegium Pharmaceutical (COLL) - The Globe and Mail
Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate GrowthSlideshow (NASDAQ:COLL) 2026-03-24 - Seeking Alpha
Collegium Pharmaceutical Stock Gains Momentum After Key Debt Repayment and Strong Earnings Momentum - ad-hoc-news.de
Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Volatility - Sahm
Collegium to buy ADHD medicine Azstarys for up to $785M - MSN
Insider Selling: Collegium Pharmaceutical (NASDAQ:COLL) EVP Sells 13,976 Shares of Stock - MarketBeat
Dieter David, Collegium Pharmaceutical EVP, sells $488k in stock By Investing.com - Investing.com Canada
Dieter David, Collegium Pharmaceutical EVP, sells $488k in stock - investing.com
Collegium (NASDAQ: COLL) EVP trades 13,976 shares under 10b5-1 plan - Stock Titan
Collegium Pharmaceuticals: Another M&A Episode Adds To An Intriguing Case (NASDAQ:COLL) - Seeking Alpha
Collegium Pharmaceutical stock faces scrutiny amid opioid market shifts and regulatory pressures - AD HOC NEWS
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor from Synnovation Therapeutics, Collegium to Acquire Azstarys from Corium Therapeutics - Pharmaceutical Executive
Azstarys (re-)born with Collegium’s ADHD buy - BioWorld MedTech
Collegium Pharmaceutical Expands ADHD Portfolio With AZSTARYS And Valuation Gap - simplywall.st
Needham & Company LLC Reiterates Buy Rating for Collegium Pharmaceutical (NASDAQ:COLL) - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Given Buy Rating at HC Wainwright - MarketBeat
Collegium to acquire Azstarys from Corium Therapeutics - The Pharma Letter
Collegium Pharmaceutical to Acquire AZSTARYS® for $650 Million, Expanding ADHD Portfolio and Projecting Over $50 Million Revenue in Late 2026 - Minichart
Collegium Pharmaceutical to acquire AZSTARYS for $650 million By Investing.com - Investing.com Australia
Jefferies reiterates Collegium Pharmaceutical stock Buy on ADHD deal By Investing.com - Investing.com Canada
Collegium Pharmaceutical to Acquire AZSTARYS ADHD Franchise - TipRanks
Collegium (NASDAQ: COLL) to acquire AZSTARYS in $650M ADHD expansion deal - Stock Titan
Barclays reiterates Collegium Pharmaceutical stock rating at Overweight By Investing.com - ca.investing.com
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):